Design, synthesis and evaluation of novel L-tryptophan derivatives as multifunctional agents with cholinesterase inhibition, anti-β-amyloid aggregation, anti-inflammatory, antioxidant and neuroprotection properties against Alzheimer's disease
- PMID: 40318509
- DOI: 10.1016/j.bioorg.2025.108478
Design, synthesis and evaluation of novel L-tryptophan derivatives as multifunctional agents with cholinesterase inhibition, anti-β-amyloid aggregation, anti-inflammatory, antioxidant and neuroprotection properties against Alzheimer's disease
Abstract
In our recent investigation, we conducted a systematic search for novel L-Tryptophan derivatives exhibiting marked inhibitory effects against human serum butyrylcholinesterase (hBuChE), an enzyme intricately implicated in the pathological cascade of Alzheimer's Disease (AD). Two lead compounds among these derivatives, Z165 and Z168 displayed IC50 values of 0.44 μM and 3.23 μM against butyrylcholinesterase, suggesting their promising potential for further structural optimization. Chemical modifications were subsequently undertaken to enhance the inhibitory activities of these leads, culminating in the development of compounds 4d-9, 4d-12, and 4d-13, which demonstrated IC50 values of 0.29 μM, 0.52 μM, and 0.13 μM, respectively. Furthermore, the following investigation revealed that these compounds exhibit exceptional antioxidant properties when juxtaposed with ascorbic acid. They are also proficient in inhibiting the aggregation of amyloid-beta (Aβ) peptides while concurrently displaying minimal cytotoxic effects towards BV-2 cell lines. Meanwhile the good blood-brain barrier permeability of these compounds was confirmed in PAMPA-BBB assay. Remarkably, compound 4d-13, which demonstrated the most potent inhibitory activity against butyrylcholinesterase, also afforded consistent neuroprotective effects compared with Galantamine against the injury induced by NMDA or L-(+)-Sodium glutamate in SH-SY5Y cells. Besides, 4d-13 could reduce the expression of inflammatory factors IL-1β and IL-6 dose-dependently in the LPS induced BV-2 inflammatory model. Morris water maze and step-down testing in vivo confirmed that 4d-13 could ameliorate scopolamine-induced cognitive deficits. These findings suggest that these compounds are promising leads for the development of therapeutic agents against AD.
Keywords: Alzheimer's disease; Anti-inflammatory; Antioxidant; Butyrylcholinesterase; Multitarget-directed ligands; Neuroprotection; Tryptophan-derivatives.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.